Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05052957Phase 2Recruiting

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Role: lead

NCT03104491Phase 1Recruiting

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Role: lead

NCT06680661Phase 2Recruiting

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Role: lead

NCT02158767Unknown

Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.

Role: lead

NCT03939585Phase 1Withdrawn

Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

Role: lead

NCT04059757Phase 2Withdrawn

Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD

Role: lead

All 6 trials loaded